Header

Title

EIB President welcomes COVAX vaccine deliveries in 100 countries


Summary

More than one hundred economies have received life-saving COVID-19 vaccines from COVAX, the global mechanism for equitable access to COVID-19 vaccines. The milestone comes 42 days after the first COVAX doses were shipped and delivered internationally, to Ghana on February 24th.


Seo Title

[EIB President welcomes COVAX vaccine deliveries in 100 countries]


Seo Description

[More than one hundred economies have received life-saving COVID-19 vaccines from COVAX, the global mechanism for equitable access to COVID-19 vaccines. The milestone comes 42 days after the first COVAX doses were shipped and delivered internationally, to Ghana on February 24th. ]


Header

Title

EIB President welcomes COVAX vaccine deliveries in 100 countries


Summary

More than one hundred economies have received life-saving COVID-19 vaccines from COVAX, the global mechanism for equitable access to COVID-19 vaccines. The milestone comes 42 days after the first COVAX doses were shipped and delivered internationally, to Ghana on February 24th.


Seo Title

[EIB President welcomes COVAX vaccine deliveries in 100 countries]


Seo Description

[More than one hundred economies have received life-saving COVID-19 vaccines from COVAX, the global mechanism for equitable access to COVID-19 vaccines. The milestone comes 42 days after the first COVAX doses were shipped and delivered internationally, to Ghana on February 24th. ]


Content

Text with image (text_with_image)

(text)

  • The COVAX Facility has now delivered life-saving vaccines to over 100 economies since making its first international delivery to Ghana on February 24th
  • So far, more than 38 million doses of vaccines from manufacturers AstraZeneca, Pfizer- BioNTech and Serum Institute of India (SII) have now been delivered, including 61 economies eligible for vaccines through the Gavi COVAX Advance Market Commitment
  • COVAX aims to supply vaccines to all participating economies that have requested vaccines, in the first half of 2021, despite some delays in planned deliveries for March and April.

More than one hundred economies have received life-saving COVID-19 vaccines from COVAX, the global mechanism for equitable access to COVID-19 vaccines. The milestone comes 42 days after the first COVAX doses were shipped and delivered internationally, to Ghana on February 24th.

The President of the European Investment Bank Werner Hoyer welcomed confirmation of COVAX delivering of COVID-19 vaccines around the world.

“As part of Team Europe the European Investment Bank is pleased to provide EUR 400 million for COVAX, representing the EIB’s largest ever support for global public health. COVAX has already provided vaccines to vulnerable groups and front-line workers and brought hope to millions more. COVAX demonstrates the benefit of global cooperation to tackle the shared challenge of COVID. Congratulations to the COVAX team and global partners in 100 countries around the world. Together we are ensuring equitable access to vaccines and together we are directing our efforts towards a global recovery.” said Werner Hoyer, President of the European Investment Bank.

In December the European Investment Bank agreed €400 million of financing to support the participation of low and middle income economies in COVAX Advance Market Commitment (COVAX AMC) and accelerate up-front investment essential to deliver vaccine doses as soon as they become available.

This rapidly approved financing, guaranteed by the European Fund for Sustainable Development and alongside €100 million grant support from the European Commission to COVAX AMC, is already supporting access to safe and effective COVID-19 vaccines in 92 low and middle-income countries.

The EIB is in discussions with Gavi, the vaccine alliance, about new financing to further scale up access to COVID-19 vaccines by high-risk and vulnerable populations in low and middle-income countries.

Follow up EIB support could be agreed in the coming months following due diligence and subject to the final approval of the EIB’s governing bodies.

“In under four months since the very first mass vaccination outside a clinical setting anywhere in the world, it is tremendously gratifying that the roll-out of COVAX doses has already reached one hundred countries,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance. “COVAX may be on track to deliver to all participating economies in the first half of the year yet we still face a daunting challenge as we seek to end the acute stage of the pandemic: we will only be safe when everybody is safe and our efforts to rapidly accelerate the volume of doses depend on the continued support of governments and vaccine manufacturers. As we continue with the largest and most rapid global vaccine rollout in history, this is no time for complacency.”

“COVAX has given the world the best way to ensure the fastest, most equitable rollout of safe and effective vaccines to all at-risk people in every country on the planet,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “If we are going to realize this great opportunity, countries, producers and the international system must come together to prioritize vaccine supply through COVAX. Our collective future, literally, depends on it.”

COVAX has now delivered more than 38 million doses across six continents, supplied by three manufacturers, AstraZeneca, Pfizer-BioNTech and the Serum Institute of India (SII). Of the over 100 economies reached, 61 are among the 92 lower-income economies receiving vaccines funded through the Gavi COVAX Advance Market Commitment (AMC).

Despite reduced supply availability in March and April – the result of vaccine manufacturers scaling and optimising their production processes in the early phase of the rollout, as well as increased demand for COVID-19 vaccines in India – COVAX expects to deliver doses to all participating economies that have requested vaccines in the first half of the year.

According to its latest supply forecast, COVAX expects to deliver at least 2 billion doses of vaccines in 2021. In order to reach this goal, the COVAX Facility will continue to diversify its portfolio further, and will announce new agreements with vaccine manufacturers in due course.

Furthermore, in March it was announced that the United States government will host the launch event for the 2021 Gavi COVAX AMC Invest Opportunity to catalyse further commitment and support for accelerated access to vaccines for AMC-supported economies. An additional US$2 billion is required in 2021 to finance and secure up to a total of 1.8 billion donor-funded doses of vaccines. COVAX is also working to secure additional sourcing of vaccines in the form of dose-sharing from higher income countries.

Notes to editors

Full announcement

The list of 102 Facility participants that have received a combined total of 38,392,540 doses of COVAX-delivered vaccines so far is as follows (in alphabetical order):

Afghanistan, Albania, Algeria, Andorra, Angola, Argentina, Armenia, Azerbaijan, Bahamas, Bahrain, Barbados, Belize, Benin, Bermuda, Bolivia (Plurinational State of), Bosnia and Herzegovina, Botswana, Brazil, Brunei Darussalam, Cabo Verde, Cambodia, Canada, Colombia, Congo (DRC), Costa Rica, Côte d'Ivoire, Djibouti, Dominica, Dominican Republic, Ecuador, Egypt, El Salvador, Eswatini, Ethiopia, Fiji, Gambia, Georgia, Ghana, Grenada, Guatemala, Guyana, Honduras, India, Indonesia, Iran (Islamic Republic of), Iraq, Jamaica, Jordan, Kenya, Kosovo, Lao People's Democratic Republic, Lebanon, Lesotho, Liberia, Malawi, Maldives, Mali, Mauritius, Mongolia, Montenegro, Morocco, Mozambique, Nauru, Nepal, Nicaragua, Nigeria, North Macedonia, Oman, Palestine, Paraguay, Peru, Philippines, Qatar, Republic of Korea, Republic of Moldova, Rwanda, Samoa, Sao Tome and Principe, Saudi Arabia, Senegal, Serbia, Sierra Leone, Solomon Islands, Somalia, South Sudan, Sri Lanka, St. Lucia*, Sudan, Suriname, Taiwan, Tajikistan, Timor-Leste, Togo, Tonga, Trinidad and Tobago, Tunisia, Tuvalu, Uganda, Uruguay, Uzbekistan, Viet Nam, Yemen.

*100th Facility participant to receive a COVAX delivery

About COVAX

COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, is co-convened by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance Gavi) and the World Health Organization (WHO) – working in partnership with UNICEF as key implementing partner, developed and developing country vaccine manufacturers, the World Bank, and others. It is the only global initiative that is working with governments and manufacturers to ensure COVID-19 vaccines are available worldwide to both higher-income and lower-income countries.